Abstract:Abstract Background and Aims Unfractionated heparin (UFH) and low molecular-weight heparin (LMWH) are the most commonly used anticoagulants in haemodialysis (HD). While effective in preventing clotting, they are also associated with complications including increased risk of bleeding and heparin induced thrombocytopenia. The contact activation system is commonly assumed to be the main trigger of coagulation during HD, through autoactivation of factor (F)XII upon contact with the dialyser. FXII deficient individuals do not have an increased risk of bleeding which makes activated FXII (FXIIa) an attractive drug target as it has the potential to inhibit clotting without disrupting haemostasis. The aim of the study was to evaluate the efficacy of CSL312, a monoclonal, humanized IgG4 antibody against activated FXII (FXIIa), in preventing intradialytic coagulation. Method An ex vivo haemodialysisis model was used to test the efficacy of CSL312 as an anticoagulant. CSL312 (400 μg/mL) was compared to standard doses of UFH, LMWH and citrate anticoagulation. The antibody was provided by CSL Limited. Anticoagulant-free haemodialysisis was used as control. Whole-blood was collected from 12 healthy adult donors in blood-transfer bags containing citrate to prevent clotting before dialysis. Each donor provided blood for two HD-sessions, using different anticoagulants. The blood was dialyzed for one hour through paediatric polysulfone high-flux dialysers. Right before the start of HD, calcium was added to reverse the anticoagulant effect of citrate, except in the citrate group. Blood was sampled before and at 5, 15, 30 and 60 minutes after HD start. To quantify the activity of the contact system, the concentrations of enzyme-inhibitor complexes of antithrombin (AT) or C1-inhibitor (C1INH) in conjunction with FXIIa, FXIa, kallikrein, MASP-1, MASP-2 and thrombin were measured in plasma using enzyme-linked immunosorbent assays. Results Using CSL312 to inhibit FXIIa protease activity (n = 5), clotting occurred in all tests (at 30, 31, 36, 49 and 50 minutes) with a mean clotting time of 39.2 minutes compared to 17 and 30 minutes using no anticoagulation (n = 2). No clotting was evident with other anticoagulants. Using CSL312, the plasma concentration of FXIIa-C1INH at 15 minutes was significantly higher than at baseline (mean 26.2 (SD 9.08) vs mean 17.6 (SD 10.6) μg/mL, p = 0.011). Conclusion FXIIa inhibition using a monoclonal antibody does not provide sufficient anticoagulation during HD. This suggests that the contact system may not be solely responsible for clotting during HD.

[Effect of blood purification materials and anticoagulants on the contact activity of factor XI]

EFFECT OF HEPARIN ON ACTIVATION OF PLATELET FUNCTION IN PATIENTS DURING RADIOFREQUENCY CATHETER ABLATION

Engineering of hemocompatible and antifouling polyethersulfone membranes by blending with heparin-mimicking microgels

Preparation of an anticoagulant polyethersulfone membrane by immobilizing FXa inhibitors with a polydopamine coating

Titanium is a potent inducer of contact activation: implications for intravascular devices

Combination of polycarboxybetaine coating and factor XII inhibitor reduces clot formation while preserving normal tissue coagulation during extracorporeal life support

Antithrombotic coating with sheltered positive charges prevents contact activation by controlling factor XII–biointerface binding

Facile Preparation of Heparinized Polysulfone Membrane Assisted by Polydopamine/Polyethyleneimine Co-Deposition for Simultaneous Ldl Selectivity and Biocompatibility

#949 Factor XIIa inhibitory antibody does not provide sufficient anticoagulation in ex vivo hemodialysis

Quantitative Determination of Activated Coagulation Factor XI As an Impurity in Therapeutic Immunoglobulins from Chinese Blood Fractionation Companies.

Dual surface modification of polydimethylsiloxane (PDMS) with antithrombin-heparin complex (ATH) and tissue plasminogen activator (t-PA) for enhanced antithrombotic activity

Impact of surface coating and systemic anticoagulants on hemostasis and inflammation in a human whole blood model

Surface plasmon resonance analysis to evaluate the importance of heparin sulfate groups' binding with human aFGF and bFGF

Immobilizing argatroban and mPEG-NH2 on a polyethersulfone membrane surface to prepare an effective nonthrombogenic biointerface

Multistage Anticoagulant Surfaces: A Synergistic Combination of Protein Resistance, Fibrinolysis, and Endothelialization

Predictive value for increased activated factor XI activity in acute venous thromboembolism

Flexible inner surface of polysulfone membranes prevents platelet adhesive protein adsorption and improves antithrombogenicity in vitro

Immobilized Heparin and Its Anti-Coagulation Effect on Polysulfone Membrane Surface

Factor XII activation markers do not reflect FXII dependence of thrombin generation induced by polyvinylchloride

The Effect of Anticoagulant Choice on Apparent Total Antioxidant Capacity using Three Different Methods

EFFECTS OF ACTIVE FRACTIONS FROM ENDOVASCULAR LIQUID EMBOLIC AGENT ON BLOOD COAGULATION IN VITRO